HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate...
Hence then, the article about akeso advances io2 0 adc2 0 strategy first patient dosed in phase ii study of trop2 nectin 4 bispecific adc ak146d1 combined with ivonescimab in breast cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer )
Also on site :
- ‘Destroy All Girls’ Review: A Young Jersey Woman Joins a Group of Itinerant Skater Dudes in a Hip and Evocative Drama
- 1969 Hit, Reimagined by Reba McEntire Decades Later, Ranked Among ‘Greatest Country Songs of All Time’
- Jim Morrison Said His Parents Were Dead. 62 Years Ago This Week, His Father May Have Started the Vietnam War. Morrison Defined Its Destruction.